Day 1 (Hepatitis Day)
A New Era in Viral Hepatitis
7.30-17.00 Registration
8.30-8.40 Wellcome
8.40-10.00
Plenary session 1
The current standard-of-care triple therapy for genotype-1 infected patients
Chair: Mircea Grigorescu, Vlad Ratziu, Anca Trifan
8.40-8.55 Global epidemiology, detection and access to therapy in Europe
Ioan Sporea, Romania
8.55-9.10 How to optimize triple therapy with 1st generation of protease inhibitors in genotype-1 patients
Adrian Goldis, Romania
9.10-9.25 How to manage side effects of triple therapy with 1st generation of protease inhibitors
Marina Maevskaya, Russia
9.25-9.40 Who should be treated now and who can wait
Iulia Simionov, Romania
9.40-10.00 Discussion
10.00-10.20 Coffee break
10.20-12.00
Plenary session 2
New antiviral regimens on horizon: How should we treat hepatitis C starting with 2015
Chair: Liana Gheorghe, Simona Ruta, Susanne Beckebaum
10.20-10.35 Hepatitis C – a virological perspective
Simona Ruta, Romania
10.35-10.50 New antiviral therapy in special populations: liver cirrhosis and liver transplant recipients
Susanne Beckebaum, Germany
10.50-11.05 Predictive factors of virological response to triple therapy
Bela Hunyady, Hungary
11.05-11.20 Advantages of the 2nd generation of IFN-based triple therapy
Anca Trifan, Romania
11.20-11.40 IFN-free regimens: protease, polymerase and NS5A inhibitors – the cocktail of the future
Vlad Ratziu, France
11.40-12.00 Discussion
12.00-13.30 Lunch
12.00-13.30 Luncheon sessions with experts (limited places available)
WORKSHOP 1 (30 places available)
Transilvania Room
From trials to clinical practice in antiviral therapy for hepatitis C – current critical points in patients management (patients’ selection and monitoring during therapy, response assessment, management of adverse events)
Chairs: Vlad Ratziu, Speranta Iacob
WORKSHOP 2 (20 places available)
Moldova Room
Antiviral therapy of HBV infection – whom, when and how to treat
Chairs: Ferruccio Bonino, Mircea Diculescu
13.30-15.20
Interactive plenary session 3 (Experts & Participants)
Facing new waves of antivirals for hepatitis C : a strategy for middle- and low-income countries
Chair: Alexandru Oproiu
Experts: Ioan Sporea, Bela Hunyady, Jerzy Jaroszewski, Marina Maevskaya, Anca Trifan, Mircea Diculescu, Liana Gheorghe,
Part I Collecting the Central & East European Experts Opinion (Carol Stanciu)
Introduction (Carol Stanciu)
· A critical overview of current guidelines
Ioan Sporea (10 min)
· How has Hungary solved the problem of
access to reimbursed DAA therapy?
Béla Hunyady (10 min)
· How has Poland solved the problem of
access to reimbursed DAA therapy?
Jerzy Jaroszewicz (10 min)
· DAA therapy in limited-budget settings – ethical, medical, and economic aspects
Oliviu Pascu (10 min)
Part 2 Critical questions, General discussion and Voting
(Oliviu Pascu, Alexandru Oproiu)
(8-10 critical questions in perspective of DAA
therapy for hepatitis C in Romania will be discussed and voted giving the opportunity of a Professionals’ Letter addressed to authorities).
15.20-15.40 Coffee break
15.40-17.30
Plenary Session 4
Hepatitis B therapy in the New Era
Chair: Ferruccio Bonino, Ioan Sporea
15.40-15.55 First line therapy for hepatitis B : nucleoside analogs (NUCs)
Marcel Tantau, Romania
15.55-16.15 The new dashboard for the individualized management of the HBV carrier
Ferruccio Bonino, Italy
16.15-16.30 Clinical applications of HBsAg quantification
Jerzy Jaroszewicz, Poland
16.30-16.45 When to stop NUCs
Oliviu Pascu, Romania
16.45-17.00 Impact of HBV therapy on long-term outcome of liver disease
Mircea Diculescu, Romania
17.00-17.20 Hepatitis delta: an update 2014
Liana Gheorghe, Romania
17.20-17.40 Discussion
Closing
Day 2 (Cirrhosis Day)
Managing Patients with Liver Cirrhosis
8.30-9.50
Plenary session 1
Assessment of pathophysiologic processes in liver diseases
Chair: Augusto Villanueva, Gabriel Becheanu, Monica Acalovschi
8.30-8.45 Non-invasive assessment of chronic liver disease
Annalisa Berzigotti, Spain
8.45-9.00 The role of pathology in diagnosis of liver disease
Elie Serge Zafrani, France
9.00-9.15 Molecular classification of hepatocellular carcinoma
Augusto Villanueva, UK
9.15-9.30 Gut microbiota and liver diseases
Razvan Iacob, Romania
9.30-9.50 Discussion
9.50-10.20 Coffee break
10.20-12.00
Plenary session 2
Complications of cirrhosis related to portal hypertension
Chair: Jaime Bosch, Cristian Gheorghe, Arun Sanyal
10.20-10.45 Acute variceal bleeding: risk, prevention and therapy
Jaime Bosch, Spain
10.45-11.00 Portal vein thrombosis and anti-coagulation in liver cirrhosis
Zeno Sparchez, Romania
11.00-11.15 Bacterial infections in cirrhosis
Dana Dobru, Romania
11.15-11.40 Hepatic encephalopathy
Arun Sanyal, USA
11.40-12.00 Discussion
12.00-13.30 Lunch, Ballroom foyer
12.00-13.00 Luncheon sessions with experts (limited places available)
Workshop 1
(30 places available)
Transilvania Room
Complications related to portal hypertension – management in current clinical practice
Chair: Jaime Bosch, Cristian Gheorghe
Workshop 2
(20 places available)
Moldova Room
Treating hepatocellular carcinoma in a multidisciplinary team
Chair: Fabio Piscaglia, Adina Croitoru
13.30-15.00
Plenary session 3
Liver cancer
Chair: Fabio Piscaglia, Ioana Lupescu, Adina Croitoru
13.30-13.45 Screening and diagnosis of HCC
Monica Acalovschi, Romania
13.45-14.05 Resection and transplantation for HCC
Irinel Popescu, Romania
14.05-14.20 Percutaneous ablation therapy for HCC
Fabio Piscaglia, Italy
14.20-14.55 Chemo and radioembolization for HCC
Mugur Grasu, Romania
14.35-14.50 Systemic therapy for HCC
Markus Peck-Radosavljevic, Austria
14.55-15.15 Discussion
15.15-15.35 Coffee break
15.35-17.05
Plenary session 4
Liver transplantation
Chair: Patrizia Burra, Irinel Popescu, Markus Peck-Radosavljevic
15.35-15.50 Correction of hereditary liver diseases by gene/cell therapy – current knowledge and future prospects
Michael Ott, Germany
15.50-16.05 Prophylaxis of HBV reinfection of the graft
Speranta Iacob, Romania
16.05-16.20 Treatment of HCV infection before and after liver transplantation
Liana Gheorghe, Romania
16.20-16.40 Long-term outcome and quality of life in liver transplant recipients
Patrizia Burra, Italy
16.40-17.05 Discussion
17.05-17.15 Closing remarks